**Saprochaete clavata Invasive Infections – A New Threat to Hematological-Oncological Patients**

Vladimir Buchta¹, Radka Bolehovská², Eva Hovorková³, Oliver A. Cornely⁴,⁵,⁶, Danila Seidel⁴,⁷ and Pavel Žák⁸*

¹ Department of Clinical Microbiology, Faculty of Medicine in Hradec Králové, Faculty Hospital in Hradec Králové, Charles University in Prague, Hradec Králové, Czechia, ² Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Králové, Faculty Hospital in Hradec Králové, Charles University in Prague, Hradec Králové, Czechia, ³ The Fingerland Department of Pathology, Faculty of Medicine in Hradec Králové, Faculty Hospital in Hradec Králové, Charles University in Prague, Hradec Králové, Czechia, ⁴ Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany, ⁵ Department I of Internal Medicine, EMM Diamond Center of Excellence in Medical Mycology, German Centre for Infection Research (DZIF), University of Cologne, Cologne, Germany, ⁶ Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany, ⁷ Department of Internal Medicine, EMM Diamond Center of Excellence in Medical Mycology, University of Cologne, Cologne, Germany, ⁸ 4th Department of Internal Medicine – Division of Hematology, Faculty of Medicine in Hradec Králové, Faculty Hospital in Hradec Králové, Charles University in Prague, Hradec Králové, Czechia

**Background:** *Saprochaete clavata* (formerly *Geotrichum clavatum*, now proposed as *Magnusiomyces clavatus*) is a filamentous yeast-like fungus that has recently been described as an emerging pathogen mostly in patients with acute leukemia.

**Methods:** This is a retrospective study of patients diagnosed with proven and probable *S. clavata* infection at the University Hospital, Hradec Králové, Czechia between March 2005 and December 2017. Previous cases were identified from the literature and FungiScope database.

**Results:** Six new cases (5 females, 1 male) of blood-stream *S. clavata* infections at the hematono- oncological department were described including epidemiological data of additional 48 patients colonized with the species. Overall, 116 strains of *S. clavata* were isolated from different clinical specimens of 54 patients; most of them belonged to the respiratory tract (60.3%). *S. clavata* was the most frequent species among arthroconidial yeasts (*Trichosporon*, *Galactomyces*, *Magnusiomyces*) recovered from the blood. All our patients with *S. clavata* infection had profound neutropenia, a central venous catheter, broad-spectrum antibiotics and antifungal prophylaxis; four had a history of a biliary tract system disease. The diagnosis was based on a positive blood culture in all patients. Four patients died of multiorgan failure and sepsis despite treatment with lipid-based amphotericin B and/or voriconazole. From the literature and FungiScope database, 67 previous cases of *S. clavata* infections were evaluated in context of our cases.
INTRODUCTION

Invasive systemic infections caused by fungi have increasingly been recognized and represent relevant cause of mortality and morbidity in growing segment of immunocompromised patients for the last decades (Miceli et al., 2011; Armstrong-James et al., 2017). The predisposing conditions are largely associated with changing spectrum of patients (age structure, co-morbidities) who are associated with a more risky therapeutic management such as an extensive surgery or aggressive treatment modalities. The majority of these risk factors are related to impaired immune defense mechanisms (hematological malignancies, immunodeficiency, HIV), often as a result of the use of immunosuppressant drugs (e.g., corticosteroids, cyclosporine, biologics), the disruption of skin and mucosa integrity (extensive surgery, catheterization, burns, mucositis), and interference of antibiotics with the indigenous microbiota (dysbiosis) (Gulcan et al., 2016; Vallabhaneni and Chiller, 2016; Vallabhaneni et al., 2016; Colombo et al., 2017). These conditions make patient population vulnerable to opportunistic pathogens including fungi such as Aspergillus, Candida, Cryptococcus or Mucorales (Vallabhaneni et al., 2016, 2017; Colombo et al., 2017). Apart from the main fungal etiology, there is a rare and taxonomically diverse group of opportunistic yeasts belonging to the genera Galactomyces, Trichosporon, and Magnusiomyces (Saprochaete), which share morphological characteristics, namely the production of arthroconidia (Hazen, 1995; Henrich et al., 2009; Repetto et al., 2012; Meletiadis and Rolides, 2013; Arendrup et al., 2014; Durán Graeff et al., 2017; Fernández-Ruiz et al., 2017). Most systemic infections caused by those arthroconidial fungi are attributable to two species, Magnusiomyces capitatus (synonym Saprochaete capitata) and Trichosporon asahii. Saprochaete clavata has emerged as a new pathogen in hematological patients in French and Italian hospitals (Lacroix et al., 2007; Camus et al., 2014; Picard et al., 2014; Vaux et al., 2014; Cornely et al., 2015; Del Principe et al., 2016; Favre et al., 2016; Esposito et al., 2018; Leoni et al., 2018). Taxonomy studies showed that S. clavata and M. capitatus are closely related (de Hoog et al., 1986; Guého et al., 1987; Smith and Poot, 1998). Today, three main clades of the arthroconidial genera are discriminated: Galactomyces and Dipodascus which are associated with the Geotrichum anamorphs, while Magnusiomyces with the Saprochaete species (De Hoog and Smith, 2004; Daniel et al., 2014). Recently, owing to the principle the one fungus, one name, dual naming has been replaced and M. capitatus (synonym S. capitata, Dipodascus capitatus) and S. clavata are now accepted (De Hoog and Smith, 2004; Hawksworth et al., 2011). In addition, Kaplan et al. (2017) have pointed out that the rules of nomenclature using the oldest valid name and the molecular phylogeny would necessitate renaming S. clavata to Magnusiomyces clavatus. Majority of characteristics of epidemiology, diagnosis and therapy of S. clavata infections are similar to those caused by M. capitatus and T. asahii (Kaplan et al., 2017). They include frequent recovery from blood, lack of specific diagnostic methods, no specific breakpoints for antifungal susceptibility test results and no optimal therapeutic regimen. Moreover, epidemiological data are scarce; there are only a few details about source and transmission of S. clavata, although it has the potential to cause outbreaks (Bougnoux et al., 2018).

Here, we present six new cases of severe infection caused by S. clavata diagnosed in the hematologic intensive care unit and epidemiological data of hospital recordings of 48 patients colonized with the yeast at the University Hospital, Hradec Králové, Czechia between March 2005 and December 2017, which are discussed in context of other S. clavata cases reported in the literature and international registry FungiScope®.

MATERIALS AND METHODS

Patient Information

Clinical data of patients with diagnosed S. clavata infection were collected including basic demographics, underlying diseases, clinical picture, antifungal therapy, and clinical outcome (Table 1). Cases with probable or proven infection classified according to the EORTC/MSG criteria were included (De Pauw et al., 2008). A literature search using PubMed for respective cases was done with the search terms “Saprochaete,” “Geotrichum,” “Dipodascus,” “Magnusiomyces,” “fungemia,” “invasive infection,” and “rare mycoses.” In addition, cases identified from the FungiScope® registry were selected (Seidel et al., 2017).

Collection and Identification of Fungal Isolates

All clinical specimens – cerebrospinal fluid, bronchoalveolar lavage (BAL) fluid, sputum, tracheal aspirate, urine, stool, wound swab, cervicovaginal fluid, punctate, skin adnexa, upper respiratory tract samples – obtained from patients hospitalized in University Hospital were routinely analyzed in mycological laboratory by inoculating onto mycological agar (SDA) to get individual colonies for further investigation such as biochemical tests (biochemical profile assessment), additional cultivation on Corn-meal agar (description of fungal micromorphology), antifungal susceptibility testing. Most of the conventional
### TABLE 1 | Baseline characteristics of Czech patients with *Saprochaete clavata* infection.

| Patient | Sex   | Age | Underlying present disease | Previous diseases/Risk factors | Chemotherapy regimen | Neutropenia (days) | Prophylaxis |
|---------|-------|-----|-----------------------------|--------------------------------|----------------------|-------------------|-------------|
|         | Male  | 45  | AML – late relapse          | AML (alloHSCT)                | Ida-HiDaraC          | ANC < 100/ml      | Antibiotic  |
|         | Female| 61  | AML – new                   | Acute GvHD                     | Chemotherapy 3 + 7   | 19                | Ciprofloxacin|
| Patient 2| Female| 63  | AML – new                   | Cholelithiasis                 |旗帜-Ida             | 45                | Acyclovir   |
| Patient 3| Female| 58  | AML – early relapse         | Cholecystectomy                | Chemotherapy 3 + 7   | 5                 | Fluconazole |
| Patient 4| Female| 50  | AML – late relapse          | HSV myocarditis                | FLAG-Ida TBI 3Gy + F and 2nd | 20                | Piperacillin/|
| Patient 5| Female| 66  | -                            | AML (autoHSCT)                 | alloHSCT            | 0                 | Taz         |
| Patient 6| Female| 66  | -                            | AML (1st alloHSCT)             | Chemotherapy 3 + 7   | 8                 | Vancomycin  |

(Continued)


### TABLE 1 | Continued

| Patient | Antifungal therapy | Antifungal susceptibility | Outcome | Cause of death |
|---------|-------------------|--------------------------|---------|---------------|
| 1       | Amphotericin B     | E: AMB 1; FLZ 4; ITZ; VRZ; VRC | Yes, 1/ No | Septic shock, MODS |
| 2       | Lipid-based AMB (Abelcet 5 mg/kg i.v.) | M: AMB 0.5; FLZ 48; ITZ; VRZ; VRC | Yes, 3/ No | Wound swab |
| 3       | Amphotericin B     | M: AMB 0.5; FLZ 48; ITZ; VRZ; VRC | Yes, 3/ No | Cerebral edema |
| 4       | Voriconazole       | M: AMB 0.5; FLZ 48; ITZ; VRZ; VRC | Yes, 3/ No | Septic shock, MODS |
| 5       | Micafungin 100 mg qD | M: AMB 1; FLZ 4; ITZ; VRZ; VRC | Survived | Septic shock, MODS |
| 6       | Lipid-based AMB (Abelcet 5 mg/kg i.v.) | M: AMB 0.5; FLZ 48; ITZ; VRZ; VRC | Yes, 3/ No | Septic shock, MODS |

**Antifungal therapy**
- Amphotericin B
- Lipid-based AMB
- Voriconazole
- Micafungin

**Outcome**
- Died
- Survived

**Cause of death**
- Septic shock
- Multiple organ dysfunction syndrome
- Wound swab
- Cerebral edema
- Septic shock
- Septic shock

**Diagnostic methods**
- MALDI-TOF mass spectrometry
- Etest
- Sensititre YeastOne
- API ID32C

**Antifungal Susceptibility Testing**

The minimum inhibitory concentration (MIC) was determined using Etest (BioMérieux, Czechia) or Sensititre YeastOne (Trek Diagnostics, BioVendor, Czechia) following the instructions of the manufacturer. Sabouraud dextrose agar (BioMérieux CZ) and Mueller-Hinton agar with 2% glucose (LabMediaServis, Czechia) were used for disk test in the period of 1995 to 2005. Later, the paper disks were replaced after availability MALDI TOF mass spectrometry (Bruker). Isolates from Patient 3 and 4 were analyzed by sequencing. DNA was extracted from the strains using a QIAamp DNA Mini Kit (Qiagen) protocol and the 18S rRNA gene was amplified using PCR (Millar et al., 2000). Sequences were analyzed using BLAST at NCBI1.

1. http://blast.ncbi.nlm.nih.gov/Blast.cgi

### Epidemiological Investigation

The incidence of *S. clavata* strains at the University Hospital Hradec Králové during the period of 1995–2017 was retrospectively evaluated based on the recordings of the laboratory information system and the criteria mentioned above. Blood, cerebrospinal fluid, BAL fluid, sputum,
tracheal aspirate, urine, and other clinical specimens were microbiologically investigated.

**Cases**

Six patients were diagnosed with an infection due to *S. clavata* in the hematologic intensive care unit at our University Hospital between 2005 and 2017 (Table 1). The median age was 50.5 years (range 45 to 66 years), five patients (83.3%) were female. Five patients were treated for acute myeloid leukemia (AML) and one for diffuse large B-cell lymphoma (DLBCL). The *S. clavata* infection in all patients was diagnosed based on a positive blood culture (Figure 2). In all patients, their management was complicated by bacterial opportunistic infections and by intensive therapy with broad-spectrum antibiotics and anticancer drugs including cytarabine. Five patients developed septic shock and required the use of artificial ventilation and/or hemodialysis. Histological investigation of necrotic samples demonstrated angioinvasivity of vessels with the tendency to disseminate to various organs, including the peritoneum, liver or spinal cord. Methenamine silver staining showed septate hyphae branching in acute angles unrecognizable from *Aspergillus* mycelium (Figures 3, 4). Four patients died of septic complications due to fungal and bacterial infections and concomitant hematologic disease. Two patients survived, but one died from an early relapse of AML later. Only one patient (no. 3) experienced a complete remission of AML. The relevant aspects of the treatment of individual patients are summarized in Table 1.

**Patient 1**
The male patient was diagnosed with AML 8 years after completing the treatment for Hodgkin lymphoma. The treatment of AML consisted of chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), which was performed during complete remission. The patient’s condition was complicated by a biliary obstruction of unknown etiology and required external biliary drainage. The first relapse of AML occurred after 4 years. The second remission of AML was not achieved after induction chemotherapy. The patient developed fever 20 days after chemotherapy (FLAG-Ida). *S. clavata* was cultured from blood. The patient developed septic shock and died of multiple organ dysfunction syndrome (MODS) 43 days after diagnosing *S. clavata*.

**Patient 2**
The female patient previously underwent resection for ovarian cancer. AML was diagnosed 3 years after the completion of the cancer treatment. A complete remission of AML was induced only after a second course of induction chemotherapy. A blood culture was positive for *S. clavata*. During a prolonged pancytopenia (absolute neutrophil count below 100/ml lasted 45 days) septic shock and MODS developed 8 days after diagnosing *S. clavata*. After the completion of treatment irreversible brain damage resulted. Subsequently, the active treatment of AML was terminated and the patient died 3 months after the diagnosis of AML.

**Patient 3**
The female patient previously underwent surgical treatment for cholecystitis. Six years later, she was diagnosed with AML. A complete remission was induced with the first course of induction therapy. *S. clavata* infection occurred after a first course of consolidation chemotherapy with high-dose cytarabine. This is the only patient who did not develop a septic shock and recovered hematopoietic function. She is still alive and remains in complete remission 87 months after allogeneic HSCT.

**Patient 4**
The female patient previously underwent resection for renal cell carcinoma as well as a resection and radiotherapy for colorectal carcinoma. She continued to suffer from a chronic anal fistula and a recurring *Clostridium* infection. Three years after undergoing radiotherapy patient was diagnosed with myelodysplastic syndrome (MDS) which developed into AML. The leukemia was treated with chemotheraphy and allogeneic HSCT (alloHSCT) using a reduced-intensity regimen. Three
Patient 5
The patient was treated for AML with chemotherapy and autologous peripheral blood stem cell transplantation. Three years later, the patient had a relapse of AML. Group B streptococci and C. albicans were cultivated from the nasopharyngeal swab. During a period of deep neutropenia, blood culture was positive for S. clavata. Eventually she developed septic shock with MODS and that resulted in death.

Patient 6
The female patient was treated for DLBCL. Due to infiltration and subsequent external biliary obstruction with a lymphoma, external drainage had to be performed. Following a course of R-CHOP chemotherapy, she developed combined hemorrhagic and septic shock with MODS. After the patient was stabilized, a surgical review identified the origin of the hepatic bleeding and liver packing was provided. Another septic shock occurred 2 weeks after candidemia caused by C. glabrata, when blood cultures became positive for S. clavata. Afterward, septic shock and MODS developed and the patient died.

RESULTS
Overall, 116 strains of S. clavata from 54 patients were obtained during the follow-up period. Almost all patients (n = 50, 92.6%) were colonized with the species, only six (11.1%) developed an infection with positive blood culture of which four had no other S. clavata findings and two were colonized – one before (biliary drainage fluid) and one after (rectal swab) fungemia. S. clavata was first identified in our institution in 2002 and was outnumbered by other arthroconidial species, especially T. asahii and M. capitatus, every year during the study period; only in 2007 it represented the most numerous species among these fungi (Figure 5). In contrast to other arthroconidial yeasts, female patients were more often colonized with S. clavata than males (55.6 vs. 44.4%). The distribution of culture positive findings suggested three main sources of S. clavata in the human body: respiratory tract and to a lesser extent, the urogenital tract and the gastrointestinal tract (Figure 6). These sources partially overlapped with colonization potential that can be expressed as repeated isolations from the same material. They are tracheal aspirate, urine samples, and punctate fluid, in which the number of isolates per material was more than doubled compared to other materials with usually one isolate per specimen (Figure 6). The exception was blood where four of six patients had repeated positive blood samples for S. clavata. In addition, S. clavata was the most common species among the arthroconidial yeasts isolated from the blood (6 × S. clavata, 3 × M. capitatus, and 2 × T. asahii) but there was no previous colonization of any catheter.

Prevalence of S. clavata in ICU patients was similar to those from standard departments (50.8% in ICU vs. 49.2% in non-ICU), but all fungemic patients were hospitalized at the oncological-hematological department. Most of S. clavata isolates came from the patients of this clinic (29.1%), followed
Incidence of Saprochaete clavata and arthroconidial fungi at the University Hospital Hradec Králové. n – number of isolates (one isolate of a given species per one patient). Other AR – number of isolates of arthroconidial yeasts (Galactomyces candidus, Magnusiomyces capitatus, Trichosporon asahii) without Saprochaete clavata.

**FIGURE 5**

by pulmonary (21.8%) and geriatric-metabolic department (14.6%) (Figure 7).

Antifungal susceptibility testing was affected by the method used during study period as the individual methods changed (Tables 2, 3). In sum, 13 strains were tested for MICs (Etest, Sensititre YeastOne) and 73 strains for inhibition zones (agar diffusion test). Based on the criteria (see section "Materials and Methods"), 12 and 55 of the strains were included in the analysis, respectively (Tables 2, 3). In general, Etest provided higher MICs than broth dilution format (Sensititre YeastOne). Our S. clavata strains displayed relatively low MICs against amphotericin B, voriconazole, itraconazole, flucytosine, and partly posaconazole, while the MICs of fluconazole and echinocandins were high (Table 2). The results of the disk test varied greatly. For voriconazole, posaconazole, flucytosine and echinocandins MICs corresponded well with the results from the disk test (Tables 2, 3).

Review of the literature and FungiScope® register revealed 73 cases of S. clavata infections in 10 countries most of which located in the Mediterranean (for details see Table 4). Only ten patients were from other regions – Germany, Serbia, China, and Czechia. The vast majority of patients manifested similar clinical signs and symptoms (neutropenia, fever, positivity of blood culture, dissemination and sepsis or septic shock, diarrhea) at time of diagnosis of S. clavata infection. The same was true for underlying conditions, including central venous catheter (CVC), broad-spectrum antibiotic therapy, aggressive chemotherapeutic regimens with cytarabine, and, in case of the French cohort, bacterial digestive decontamination (Vaux et al., 2014). Most patients were treated with voriconazole and/or lipid-based amphotericin B, but mortality rate was extremely high (>65%) (Table 4). *In vitro* and *in vivo* results confirmed that S. clavata is intrinsically resistant to echinocandins (Table 2).

**DISCUSSION**

Saprochaete clavata together with the Galactomyces, Magnusiomyces, and Trichosporon species represent rare human pathogenic fungi of heterogeneous origin, which share production of arthroconidia. S. clavata is almost exclusively confined to systemic, life-threatening infections while the clinical presentation of infections caused by other arthroconidial fungi range from superficial (Trichosporon spp.), mucosal (Galactomyces candidus), allergic (Trichosporon pneunonitis) to systemic forms (T. asahii, M. capitatus, and G. candidus) (Girmenia et al., 2005; Henrich et al., 2009; Bonifaz et al., 2010; Vaux et al., 2014; de Almeida Júnior and Hennequin, 2016; Durán Graeff et al., 2017; Esposto et al., 2018; Leoni et al., 2018; Salgueiro Fernández et al., 2018). AML is the leading underlying condition for systemic infections caused by S. clavata such as for other arthroconidial yeasts (Girmenia et al., 2005; Henrich et al., 2009; Camus et al., 2014; de Almeida Júnior and Hennequin, 2016).

All epidemiological aspects associated with S. clavata are not fully understood. Numbers of isolates of arthroconidial fungi obtained in our hospital during the period of 1995 to 2017 showed a noticeable fluctuation, which corresponded with similar course of fungemia outbreak in the French hospitals (Figure 3 in Vaux et al., 2014). That can suggest influence of some unknown epidemiological factor(s). All arthroconidial fungi are ubiquitous in nature but Trichosporon infections are more frequently described in the United States, while *M. capitatus* prevails in the Mediterranean area (Italy, France, Spain, Turkey, Greece, Tunisia, Israel, Libya, FungiScope®) (Schiemann et al., 1998; Gadea et al., 2004; Christakis et al., 2005; Girmenia et al., 2005; Garcia-Ruiz et al., 2013; Vaux et al., 2014; Trabelsi et al., 2015;
Del Principe et al., 2016; Durán Graeff et al., 2017; Esposto et al., 2018; Leoni et al., 2018; Salgüero Fernández et al., 2018). We found no correlation between temperature in the Czechia and in Eastern Bohemia and the number of isolated *S. clavata* strains during the follow-up period (data not shown).

As regards potential sources of these fungi, main suspicion falls on in-house environment (dishwasher) and food, especially milk and dairy products (Bouakline et al., 2000; Gurgui et al., 2011; Zalar et al., 2011; Vaux et al., 2014; Banjara et al., 2015; Gouba and Drancourt, 2015). It is worth mentioning interpersonal transmission among hospitalized patients as reported during the French outbreak and the potential of fly-to-human transmission as suggested by the positive *S. clavata* isolates from *Drosophila* flies (Pimenta et al., 2009; Vaux et al., 2014). In line with the reports on other arthroconidial fungi, the respiratory tract seems to be the main ecological niche colonized by *S. clavata* in debilitated patients, whereas the intestine and/or urogenital tract may be less relevant (Figure 6). Metagenomic studies have not revealed *S. clavata* in human microbiota in contrast to the species of *Galactomyces* and *Trichosporon*, which are part of the gut microbiome and together with *Candida*, *Malassezia*, and sporing molds constitute core gut mycobiota (Gouba et al., 2014; Hallen-Adams and Suhr, 2017; Auchtung et al., 2018; Li et al., 2018).

Del Principe et al., 2016; Durán Graeff et al., 2017; Esposto et al., 2018; Leoni et al., 2018; Salgüero Fernández et al., 2018). We found no correlation between temperature in the Czechia and in Eastern Bohemia and the number of isolated *S. clavata* strains during the follow-up period (data not shown).

To date, little is known about the virulence mechanisms of *S. clavata*. There is no data about biofilm production of *S. clavata*, only indirect suggestions based on a close relation between the presence of CVC and a positive blood culture (this study, Girmenia et al., 2005; Camus et al., 2014; Picard et al., 2014; Vaux et al., 2014; Del Principe et al., 2016). Compared to *T. asahii*, *S. clavata* is more genetically monomorphic (Sun et al., 2012; Vaux et al., 2014). Two main clades (A and B) of *S. clavata* were identified during the French outbreak (Vaux et al., 2014). The clinical significance of both clades was similar in most characteristics, including their susceptibility to antifungal drugs. Although clade A exhibited lower virulence expressed by longer survival of experimentally infected mice, it was responsible for most cases of the French outbreak (Vaux et al., 2014). That indicates higher human-to-human transmissibility of the clade A or its better adaptability to unknown environment (source), which can be responsible for an increased exposure of vulnerable patients to this clade (Vaux et al., 2014).

Clinically, *S. clavata* infections are difficult to distinguish from *M. capitatus* infections and the majority of other invasive mycoses. No reliable diagnostic tests are available and thus, in the absence of any specific signs and symptoms, positive blood cultivation remains indicative for this mycosis. It is difficult to establish an early diagnosis, which increases the likelihood for the optimal timing of antifungal treatment before the development of advanced and more difficult-to-control stage of the infection. There is no surprise that the mortality rate was extremely high and reached 66.6% in our patients; that was comparable to overall mortality of other reported cases (Table 4). In this way, blood culture positivity seems to represent not only diagnostic but also a poor prognostic factor.
### TABLE 2 | Review of in vitro susceptibility of Saprochaete clavata isolates to antifungal drugs.

| Specimen (n) | Drug | AMB | AFGN | MFGN | CFGN | PSZ | VRZ | ITZ | FLZ | ISZ | SFC | Source |
|--------------|------|-----|------|------|------|-----|-----|-----|-----|-----|-----|-------|
| **Methods**  |      | GM Range | GM Range | GM Range | GM Range | GM Range | GM Range | GM Range | GM Range | GM Range | GM Range |       |
| Blood (7)    | Etest | 0.955 | 32 | 3 | 36.6 | 9.97 | 0.676 | 0.794 | 18.4 |       |      | This study |
| Sputum (2)   | n\#  | 0.25–2 | 32 | 3 | 32–48 | 2–32 | 0.094–8 | 0.25–4 | 4–128 |       |      |       |
| Others§ (4)  | YeastOne | 0.574 | 1.74 | 2 | 8 | 0.285 | 0.058 | 0.092 | 6.96 | 0.091 | 0.091 |       |
| Clinical isolates (4) | CLSI | 2.25 | 4 | 0.19 | 0.88 |       |       |       |       |       |       | Pfaller et al., 2015 |
| Human/CLSI  |      | 0.22 | 2 | 6.7 | 0.25 | 0.25 | 0.27 | 19 | 0.54 |       |       | Kaplan et al., 2017 |
| Dishwasher (8) | M27-A3 | 0.125–0.5 | 2 | 2–8 | 0.25 | 0.25 | 0.25–0.5 | 16–32 | 0.125–1 |       |       |       |
| Blood (3)    | Etest | 1–1.5 | >32 | >32 | >32 | 0.19–0.5 | 0.094–0.125 |       |       |       |       |       | Picard et al., 2014 |
| Blood (3)    | YeastOne | 0.42 | 1 | 0.5 | 8 | 0.17 | 0.05 | 0.09 | 2.67 |       |       | Del Principe et al., 2016 |
| Sensititre   | 0.25–0.5 | 1 | 0.5 | 8 | 0.125–0.25 | 0.03–0.06 | 0.03–0.12 | 2–4 |       |       |       |       |
| Blood (45)   | EUCAST | 0.5 | 8 | 0.5 | 1 | 0.25 |       |       |       |       |       | Vaux et al., 2014 |
| Blood (1)    | Etest | 1 | 0.75 | 0.064 | 12 |       |       |       |       |       |       | Camus et al., 2014 |
| Blood (1)    | EUCAST | 0.25 | >4 | >4 | 0.5 | 0.5 | 32 | 0.25 |       |       |       | Fave et al., 2016 |
| Clinical isolates (4) | Etest | 1.25 | 3 | 0.56 | >32 | 0.16 | 0.13 | 20.3 | 0.014 | 16.1 |       | Durán Graeff et al., 2017 |
| Blood (1)    | MIC test | ≤0.5 |       |       |       |       |       |       |       |       |       | Liu et al., 2018 |
| Blood (18)   | YeastOne | 0.96 | 0.46 | 0.34 | 0.31 | 17.96 | 0.71 | 0.18 |       |       |       | Esposto et al., 2018 |
| Sensititre   | 0.5–1 | 0.25–1 | 0.03–1 | 0.12–0.5 | 8–64 | 0.12–4 | 0.06–0.5 |       |       |       |       |       |
| Blood (1)    | YeastOne | 0.25 | R | R | 0.25 | 0.5 | 32 | 0.12 |       |       |       | Salgüero Fernández et al., 2018 |

*Quantitative test (MIC, mg/ml); GM – geometric mean; n – number of isolates. \#The number of strains tested with Etest in brackets, AMB (7), VRZ (6), FLZ (5), PSZ (5), ITZ (3), CFGN (3), AFGN (1), MFGN (1). §Laryngeal swab, punctate, urine, drainage fluid. R = interpreted as resistant according to EUCAST standard (document not specified), AMB – amphotericin B, SFC – flucytosine, AFGN – anidulafungin, MFGN – micafungin, CFGN – caspofungin, PSZ – posaconazole, VRZ – voriconazole, ITZ –itraconazole, FLZ – fluconazole, ISZ – isavuconazole.*

---

The susceptibility of Saprochaete clavata isolates to antifungal drugs is reviewed in Table 2, with in vitro testing methods including Etest, YeastOne, CLSI, EUCAST, and MIC tests. The table provides geometric mean (GM) ranges for each antifungal drug across different specimen types and methods. The table includes drugs such as amphotericin B (AMB), anidulafungin (AFGN), micafungin (MFGN), caspofungin (CFGN), flucytosine (SFC), posaconazole (PSZ), voriconazole (VRZ), itraconazole (ITZ), and fluconazole (FLZ), with results from various studies including those by Pfaller et al., Kaplan et al., Picard et al., Del Principe et al., and Camus et al., among others. The table also notes that some tests were conducted with specific methods or standards, such as the Etest method and the EUCAST standard for interpreting resistance. The data highlights the variability in susceptibility among different isolates and specimen types, with some isolates showing higher resistance profiles to certain drugs.
Apart from blood culture, antigen detection can be useful in diagnosis of arthroconidial fungi because they share a cross-reactivity with cryptococcal glucuronoxylomannan (T. asahii, M. capitatus, Aspergillus galactomannan (G. candidus, M. capitatus), and β-D-glucan (Odabasi et al., 2006; Bonini et al., 2008; Liao et al., 2012a; Nakase et al., 2012; Trabelsi et al., 2015; de Almeida Júnior and Hennequin, 2016; Del Principe et al., 2016). In our patients, three out of five (the sixth not tested) had galactomannan index values from 0.5 to 0.7 (the other two ≤ 0.3) at the time of diagnosis of S. clavata fungemia (Table 4). Available data from other studies showed a lower sensitivity of the galactomannan test and questioned its practical use (Picard et al., 2014; Del Principe et al., 2016). In an Italian study, positive β-D-glucan test results were documented in two out of three patients (Del Principe et al., 2016). To date, the experience with the methods in S. clavata infection is little but promising results support further investigation of their clinical usefulness.

Culture-dependent identification of Galactomyces, Saprochaete, and Trichosporon is limited to AuxaColor (BioRad), API ID32C (BioMérieux) or VITEK 2 system (ID-YST card; BioMérieux). Unfortunately, none of the systems covers S. clavata. In general, the accuracy of identification of arthroconidial yeasts by these methods is not reliable (Posteraro et al., 2015). The use of phenotypic tests may be a source of misidentification, especially when cellobiose assimilation is missing (Smith and Poot, 1998; Desnos-Ollivier et al., 2014). Desnos-Ollivier et al. (2014) described about 15% of S. clavata strains that did not assimilate cellobiose. Hence, such “cellobiose-negative M. capitatus” strains may have escaped our attention in the past. Recently, the MALDI-TOF mass spectrometry (Biotyper 3.0) has displayed the most promising laboratory tool for determination of and discrimination between arthroconidial fungi, including S. clavata, even though reliability varies (Seyfarth et al., 2012; Kolecka et al., 2013). ITS, 18S rRNA or protein-coding loci (e.g., Rbp2) sequencing may be a reasonable approach to confirm results of other methods (this study, Desnos-Ollivier et al., 2014; Durán Graeff et al., 2017; Kaplan et al., 2017).

The role of antifungal susceptibility testing in the management of infections caused by arthroconidial fungi is controversial because of lack of standardized methods. Our MICs were influenced by changing methodologies during the follow-up period (Etest®, YeastOneTM), but most of them were in line with the results of other studies (Tables 2, 3). The inhibition zones corresponded well with the MICs in case of fluconazole, voriconazole, posaconazole, fluconysine, and echinocandins and disk test may serve as a tentative method for surveillance of S. clavata isolates. As no breakpoints and epidemiological cut-off are defined for S. clavata yet, interpretation of the susceptibility test results should be done with caution. One has to take into account the clinical form and course of the infection, the pharmacological profile of a given drug or drug formulation, and the presence of risk and predisposing factors in a patient (Arendrup et al., 2014).

Invasive infections caused by arthroconidial fungi typically manifest as fungemia with a tendency to disseminate in immunocompromised patients. They are characterized by a relatively high blood recovery rate and the involvement of different visceral organs such as the lungs, spleen and liver (Girmenia et al., 2005; Vaux et al., 2014; Cornely et al., 2015; Durán Graeff et al., 2017). Our S. clavata patients displayed no pulmonary symptoms, even when one patient (No. 5) was positive for biopic sample of lungs (Table 1). This is in contrast to frequently reported findings in more than half of the French outbreak patients (Vaux et al., 2014). On the other hand, two thirds of our patients have experienced cholelithiasis or cholecystitis, which has been mentioned previously in only one female patient with S. clavata infection (Del Principe et al., 2016). That could be due to a relative lack of primary bile salts as a result of gallstone formation and their lower availability for the intestinal microbiota, which converts them to secondary salts with antimicrobial effect on some bacteria and also on C. albicans (Guinan et al., 2018; Kelly et al., 2019). Alternatively, it may be the result of antibiotic therapy or cholecystectomy that can alter composition of transformation microbiota and indirectly interfere with the production of secondary salt (Theriot et al., 2016; Wang et al., 2018). Microbiota connection is supported with the digestive tract decontamination (gentamicin and/or colistin) to which more than half of French patients have been exposed and suffered from diarrhea (Vaux et al., 2014). Another risk factor in S. clavata infection is anticaner drug cytosome arabinoside (cytarabine) (Stentoft, 1990; Camus et al., 2014; Picard et al., 2014; Vaux et al., 2014; Del Principe et al., 2016) with specific effect on the neutrophil count and mucosal integrity. Preferential use of more aggressive regimens of cytarabine (≥2000 mg/m² twice daily) in recent years could contribute to S. clavata infection, like in case of five of our patients (Willemez et al., 2014).

A relatively high MIC of fluconazole (≥4 mg/l) in strains isolated from our patients suggested that the prophylactic treatment with the triazole drug could represent a selective pressure for S. clavata overgrowth. That is supported with the reports on development of breakthrough infections caused by arthroconidial yeasts in immunocompromised patients on fluconazole or echinocandin prophylaxis or empirical regimen.

**Table 3** | Antifungal susceptibility of Saprochaete clavata isolates* by disk diffusion method at the University Hospital, Hradec Králové in the period of 1995–2017.

|          | AMB | FLZ | ITZ | VRZ | PSZ | KTZ | CFGN | 5FC |
|----------|-----|-----|-----|-----|-----|-----|------|-----|
| n        | 60  | 69  | 68  | 53  | 5   | 16  | 5    | 7   |
| GM       | 12.6| 15.9| 14.8| 14.8| 20.2| 18.4| 23.6 | 8.8 |
| range    | 8–25| 6–32| 9–29| 9–33| 14–22| 18–28| 6–12 | 22–51|
| IZ50     | 13  | 18  | 14  | 20  | 19  | 25  | 9    | 35  |
| IZ90     | 9.5 | 6   | 11  | 15  | 15  | 19  |      |     |

*Only isolates that met the following criteria were included in the statistical analysis: one isolate/species per one material and per one patient. GM – geometric mean (inhibition zone in mm), n – number of strains, IZ50/IZ90 – lowest limit of inhibition zone (mm) encompassing 50%/90% of isolates tested. AMB – amphotericin B, FLZ – fluconazole, ITZ – itraconazole, VRZ – voriconazole, PSZ – posaconazole, CFGN – caspofungin, 5FC – flucytosine, KTZ – ketoconazole.
## TABLE 4 | Summary of case characteristics of *Saprochaete clavata* infections from literature and FungiScope®.

| Study          | Country | Sex | Age | Underlying disease | Risk factor<sup>2</sup> | Clinical form | Positive specimen | Lab diagnosis          | Drug         | Dosage | Duration | Outcome  |
|----------------|---------|-----|-----|-------------------|-------------------------|---------------|-------------------|----------------------|--------------|--------|----------|----------|
| Lacroix et al., 2007 | France  | M   | 14  | AML               | CVC, cytarabine         | Sepsis        | Blood             | Blood culture        | E: AMB       | ns     | 1 day    | Survived |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + VRZ      |             |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      | T: VRZ + SFC        |             |        |          |          |
|                |         | M   | 59  | AML               | CVC, cytarabine         | BSI           | Blood, urine, biopsy (skin) | Blood culture, GM negative | P: CFGN     | ns     | 7 days   | Survived |
|                |         |     |     |                   |                          |               |                   |                      | E: CFGN + L-AMB      | 3 mg/kg/d (L-AMB) | 7 days |         |          |
|                |         |     |     |                   |                          |               |                   |                      | E: L-AMB + PSZ       | 4 days      |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + 5FC + PSZ | 5 mg/kg/d (L-AMB) | 7 days |         |          |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + 5FC + VRZ | 21 days     |        |          |          |
| Picard et al., 2014 | France | F   | 46  | AML               | CVC, cytarabine, digestive decontamination (GEN, COL), PIP, AMI, VAN, CIP | BSI, disseminated | Blood, stool, TAS | Blood culture, GM positive | P: PSZ     | ns     | 24 days  | Died     |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + VRZ       |             |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      | E: CFGN               |             |        |          |          |
|                |         | M   | 70  | AML               | CVC, digestive decontamination (GEN, COL), PIP, AMI, VAN, CIP | BSI, pulmonary | Blood             | Blood culture        | E: CFGN     | ns     | 4 days   | Died     |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + VORI      |             |        |          |          |
| Del Principe et al., 2016 | Italy  | F   | 36  | AML               | CVC, cytarabine, neutropenia, PIP-Taz, MER | BSI, disseminated | Blood, stool, TAS | Blood culture        | E: CFGN     | ns     | 6 days (CFGN) | Survived |
|                |         |     |     |                   |                          |               |                   |                      | T: L-AMB + VRZ (after discharge) | 350 mg qd iv | 100 days (L-AMB) |         |
|                |         |     |     |                   |                          |               |                   |                      | 200 mg bid oral      |             |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      | 15 days (FungiScope) |           |        |          |          |
|                |         | F   | 50  | MC lymphoma       | CVC, cytarabine, steroids, neutropenia (<500 mm<sup>3</sup>), PIP-Taz, MER, cytarabine | Pneumonia, cholecystitis, hepatosplenic abscesses | Blood, CVC | Blood culture, betaG > 500 pg/ml, GM negative | T: L-AMB     | 200 mg qd iv | 10 days (L-AMB) | Died     |
|                |         |     |     |                   |                          |               |                   |                      | VRZ (after discharge) | 350 mg qd iv |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      |                        | 47 days (L-AMB) |        |          |          |
|                |         | M   | 21  | AML               | Methylprednisolone, neutropenia (<500 mm<sup>3</sup>), PIP-Taz, MER, cytarabine | Splenic abscesses | Blood, CVC | Blood culture, betaG negative, GM negative | T: L-AMB     | 200 mg qd iv | 12 days (L-AMB) | Survived |
|                |         |     |     |                   |                          |               |                   |                      | VRZ (after discharge) | 600 mg bid oral |        |          |          |
|                |         |     |     |                   |                          |               |                   |                      |                        | 1 day (VRZ)    |        |          |          |

(Continued)
| Study                        | Country | Sex | Age | Underlying disease                  | Risk factor\(^a\) | Clinical form                               | Positive specimen   | Lab diagnosis  | Drug | Dosage | Duration | Outcome          |
|-----------------------------|---------|-----|-----|-------------------------------------|-------------------|---------------------------------------------|---------------------|---------------|------|--------|-----------|-----------------|
| Vaux et al., 2014           | France  | F   | 15  | AML                                | 63 (15\()^c\)     | Neutropenia (\(<500\) mm\(^3\); 90\%), cytarabine (78.3\%) | Blood, stool, BAL, | Blood culture | ns    | ns     | ns        | 24 (80\%) died |
|                             |         |     |     |                                     | (mean) ALL (20%)  | pulmonary (40\%), diarrhea (61.5\%)        | TAS (86.7\%)        |               |      |        |           |                 |
|                             |         | M   | 32  | AML                                |                   | Cytarabine, IMI, VAN, MET                    | Blood, stool, ascites | Blood culture, GM negative | E: CFGN | 50 mg qd iv | 8 days (CFGN) | Survived       |
|                             |         |     |     |                                     |                   | Sepsis, peritonitis, Hepatic lesions        |                     |               | T: VRZ   | 300 mg qd iv | 35 days (VRZ iv) |                 |
|                             |         |     |     |                                     |                   | Blood, CVC                                 |                     |               |          | 100 mg qd iv | >270 days (VRZ po) |                 |
| Camus et al., 2014          | France  | M   | 27  | Aplastic anemia                    |                   | CVC, neutropenia, prednisone, PIP-Taz, AMI, MET | BSI, disseminated | Blood culture | E: CFGN | 50 mg qd iv | 2 days (CFGN) | Survived       |
|                             |         |     |     |                                     |                   |                                             |                     |               | T: L-AMB + VRZ | 200 mg bid iv | 55 days (L-AMB + VRZ) |                 |
|                             |         |     |     |                                     |                   |                                             |                     |               | T: L-AMB | 400 mg bid iv | (VRZ)        |                 |
| Favre et al., 2016          | France  | M   | 6   | Hemophagocytic lymphohistiocytosis |                   | Auto BMT, CVC, neutropenia                  | BSI                 | Blood culture | E: CFGN | 250 mg qd iv | 8 days | Died           |
|                             |         |     |     |                                     |                   |                                             |                     |               | T: AMB-D  | ns         | 18 days |                |
|                             |         |     | 37  | AML (relapse)                       |                   | Neutropenia (\(<500\) mm\(^3\))            | BSI                 | Blood culture | T: VRZ   | 240 mg bid iv | 8 days | Survived       |
|                             |         | F   |     |                                     |                   | Disseminated (CNS, liver, spleen)           | PCR (CSF)           |                 |          | 200 mg bid oral | 6 days |                |
|                             |         |     | 17  | AML                                |                   |                                             |                     |                 | E: L-AMB | 250 mg qd iv | 12 days | Alive, ongoing therapy |
|                             |         |     |     |                                     |                   |                                             |                     |                 | T: L-AMB | 250 mg qd iv | 27 days |                |
|                             |         |     |     |                                     |                   |                                             |                     |                 | T: 5FC    | 1000 mg 4x oral | L-AMB + 5FC |                |
|                             |         |     |     |                                     |                   |                                             |                     |                 | T: VRZ   | 200 mg bid iv | 5 days |                |
|                             |         |     |     |                                     |                   |                                             |                     |                 |          |          | L-AMB + 5FC + VRZ |                 |

(Continued)
TABLE 4 | Continued

| Study               | Country | Sex | Age | Underlying disease | Risk factor | Clinical form | Positive specimen | Lab diagnosis | Drug | Dosage          | Duration | Outcome   |
|---------------------|---------|-----|-----|-------------------|-------------|---------------|-------------------|---------------|------|-----------------|----------|-----------|
| Fungiscope          | Spain   | M   | 48  | Lymphoma          | aloHSCT, neutropenia (<500 mm³) | BSI, disseminated (CNS, liver, lung, spleen) | Blood | Blood culture, PCR (pleural fluid) | E: L-AMB | 400 mg qd iv | 3 days (2 days with VRZ) | Died     |
|                     |         |     |     |                   |             |               |                   |               | T: VRZ | 200 mg bid iv   |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: L-AMB | 400 mg qd iv     |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: VRZ | 200 mg bid iv     |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: SFC | 37.5 mg 4x iv     |          |           |
|                     |         |     |     |                   |             |               |                   |               | 2nd p: PSZ | 300 mg qd tab |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: L-AMB | 400 mg qd iv     |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: SFC | 37.5 mg 4x iv     |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     | Germany | M   | 55  | AML (relapse)      | aloHSCT (PBSC), neutropenia (<500 mm³), ICU | Blood | Blood | Blood culture | E: L-AMB | 290 mg qd iv | 5 days | Survived |
|                     |         |     |     |                   |             |               |                   |               | T: VRZ | 200 mg bid po    |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     | Serbia  | M   | 19  | ALL (relapse)      | Not neutropenic | BSI, pulmonary | Blood | Blood culture | E: CFGN | 50 mg qd iv | 4 days | Died     |
|                     |         |     |     |                   |             |               |                   |               | T: CFGN | 50 mg qd iv |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     | Italy   | M (11) | ns | AML (8), Hodgkin lymphoma (3), aplastic anemia (2), surgery (3), ns (2) | ns | BSI | Blood | Blood culture | ns | ns | ns | ns |
|                     | Esposto |         |     |                   |             |               |                   |               |        |                 |          |           |
|                     | et al., 2018 |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     | China   | M | 10  | Acute lymphocytic leukemia | Neutropenia, pancreatitis | BSI, pulmonary | Blood | Blood culture, GM 1.33, 6.03, beta-G 746 pg/ml | E: MFGN | 50 mg qd iv | 8 days (mono) | Survived |
|                     |         |     |     |                   |             |               |                   |               | T: VRZ | 150 mg iv q12h  |          |           |
|                     |         |     |     |                   |             |               |                   |               | T: MFGN + VRZ | 100 mg qd iv + 100 mg iv q12h | 15 days (mono) |           |
|                     |         |     |     |                   |             |               |                   |               | T: MFGN + L-AMB | 27 mg iv qd | 40 days (MFGN + VRZ) |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     |         |     |     |                   |             |               |                   |               |        |                 |          |           |
|                     | Spain   | M   | 47  | Lymphoma          | Neutropenia, prednisone, alloHSCT | BSI, skin | Blood, skin biopsy Brain abscess | Blood culture | T: L-AMB | 5 mg/kg/d | 60 days | Died     |
|                     |         |     |     |                   |             |               |                   |               | T: SFC | 37.5 mg 4x iv |          |           |

(Continued)
### TABLE 4 | Continued

| Study   | Country | Sex | Age | Underlying disease | Risk factor[^a] | Clinical form | Positive specimen | Lab diagnosis | Drug | Dosage | Duration | Outcome |
|---------|---------|-----|-----|---------------------|-----------------|---------------|------------------|--------------|------|--------|----------|---------|
| This study | Czechia | M   | 45  | AML                 | CVC, cytarabine, neutropenia, alloHSCT, acute GvHD, cholelithiasis, cholecystectomy, biliary drainage | Blood          | Blood culture, GM 0.70 (-2 days)* | T: AMB-D    | 75 mg qd iv | 200 mg bid po | 27 days | Died   |
|         |         |     |     |                     |                 |               |                  | T: VRZ      | 75 mg qd iv | 200 mg bid po | 7 days   |         |
| F      | 61      | AML |     |                     | CVC, cytarabine, neutropenia, chronic pancreatitis, cholelithiasis, cholecystectomy | Blood          | Blood culture, GM 0.55 (+3 days)* | T: AMB-D    | 75 mg qd iv | 400 mg qd iv | 15 days | Died   |
|         |         |     |     |                     |                 |               |                  | T: AMB-LC   | 400 mg qd iv | 200 mg bid po | 6 days   |         |
| F      | 63      | AML |     |                     | CVC, neutropenia (<500 mm³), cholelithiasis, cholecystectomy, cytarabine | Blood          | Blood culture, GM 0.18, PCR (sequencing) | T: AMB-LC   | 400 mg qd iv | 200 mg bid po | 4 days   | Survived |
|         |         |     |     |                     |                 |               |                  | T: VRZ      | 400 mg qd iv | 200 mg bid po | 9 days   |         |
| F      | 58      | AML |     |                     | CVC, neutropenia (<500 mm³), cytarabine, alloHSCT, acute GvHD | Blood, rectum  | Blood culture, GM 0.50 (only with 3rd blood culture), PCR (sequencing) | T: AMB-D    | 50 mg qd iv | 400 mg qd iv | 2 days   | Died   |
|         |         |     |     |                     |                 |               |                  | T: AMB-LC   | 200 mg qd iv | 400 mg qd iv | 7 days   |         |
| F      | 50      | AML |     |                     | CVC, cytarabine, neutropenia, autoHSCT | Blood, wound swab | Blood culture   | T: AMB-D    | 50 mg qd iv | 200 mg qd iv | 4 days   | Died   |
| F      | 66      | Lymphoma |     |                     | CVC, cytarabine, neutropenia, cholelithiasis, cholecystectomy, Candida glabrata fungemia | BSI, cholelithiasis, cholecystectomy, | Blood culture, GM 0.31 | T: MFGN (C. glabrata fungemia) | 100 mg qd iv | 200 mg bid po | 12 days (C. glabrata fungemia) | Died   |
|         |         |     |     |                     |                 |               |                  | T: VRZ      | 100 mg qd iv | 200 mg bid po | 3 days (S. clavata) |         |

[^a]: Disease-related risk factors that were present at any time during procedure. BSI: bloodstream infection.
Voriconazole remains the drug of choice for *S. clavata* infections despite not all strains display optimal in vitro susceptibility results (see Patient No. 2, Table 1). This is in line with the recommendation from a panel of experts (Arendrup et al., 2014). On the other hand, liposomal amphotericin B may be an effective alternative; all three Italian patients responded to liposomal amphotericin B and two of them survived (the third died of another cause) (Del Principe et al., 2016). The use of combination therapy remains controversial. Voriconazole and liposomal amphotericin B have provided mixed successes. Adding flucytosine to those drugs as suggested by Lacroix’s report and supported in vitro data could represent a potentially useful therapeutic modality for both (Tables 2–4) (Lacroix et al., 2007; Picard et al., 2014; Favre et al., 2016; Leoni et al., 2018; Liu et al., 2018). There are limited data about the therapeutic usefulness of posaconazole and isavuconazole (Miceli and Kauffman, 2015; Brunetti et al., 2016). Although the spectrum of activity of these antifungal drugs includes arthroconidial fungi, their MICs suggest that both drugs could be slightly less active on *S. clavata* than voriconazole, maybe, due to a lack of in vivo fungicidal activity and/or inadequate pharmacokinetics (Walsh et al., 1990; Girmenia et al., 2014; Pfaller et al., 2015; Durán Graeff et al., 2017; Esposto et al., 2018; Desnos-Ollivier et al., 2019). This may follow from variable host liver metabolizer status like in voriconazole (CYP2C19 gene polymorphism) or problematic bioavailability of oral suspension of posaconazole even when the latter problem can be overcome by new formulation of delayed release tablets (Owusu Obeng et al., 2014; Yi et al., 2017; Mason et al., 2019).

The two main pillars in successful management of infections caused by *S. clavata* are the early administration of antifungal drugs and the control of underlying conditions. While antifungal can safe life for a limited period of time, long-term survival is dependent on the recovery of the underlying hematological disease or neutropenia (Camus et al., 2014; Picard et al., 2014; Del Principe et al., 2016). The only of our six patient who survived achieved a complete hematopoietic regeneration and presented fewer risk factors (shorter period of deep neutropenia, no urinary catheter, no nasogastric tube, and no parenteral nutrition) with less severe symptomatology (lack of septic shock with MODS) (Table 1).

Recovery of *S. clavata* from the blood manifests dissemination stage of life-threatening infection and underlines the urgent need to move the timing of the institution of antifungal therapy before positivity of the blood culture. That supports empirical approach to the therapy using stratification of patients and to start initial treatment based on presence or the accumulation of risk factors, urgency of clinical situation, and availability of other laboratory and clinical data (antigen detection, imaging techniques, previous microbiological findings), including response to current therapy. Therefore, management of *S. clavata* infections is complex that requires close cooperation between the clinicians, microbiologists and epidemiologists.

*Saprochaete clavata* represents an emerging opportunistic fungal pathogen closely associated with AML. Most of the clinical and epidemiological characteristics overlap with the infections...
caused by other arthroconidial fungi, especially *M. capitatus* and *T. asahii*. Primary source of *S. clavata* is unknown but this yeast is able to colonize humans and under favorable conditions, such as deep and long immunosuppression, to overcome debilitated defense mechanisms and cause life-threatening infection. The prognosis of these invasive infections is generally poor due to lack of the specific clinical signs and symptoms, reliable diagnostic methods, and a limited efficacy of available antifungal drugs. The diagnosis of *S. clavata* infections is usually based on positivity of blood culture; detection of beta-D-glucan or *Aspergillus* galactomannan can be helpful. The optimal treatment has not been established yet; best results are connected with the application of voriconazole or liposomal amphotericin B, but successful outcome is usually critically dependent on the recovery of underlying conditions associated with immune dysfunction or deficiency.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding author.

**REFERENCES**

Arendrup, M. C., Boechtou, T., Akova, M., Meis, J. F., Cornely, O. A., Lortholary, O., et al. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. *Clin. Microbiol. Infect.* 20(Suppl. 3), 76–98. doi: 10.1111/1469-0691.12360

Armstrong-James, D., Bicanic, T., Brown, G. D., Hoving, I. C., Meintjes, G., Nielsen, K., et al. (2017). AIDS-related mycoses: current progress in the field and future priorities. *Trends Microbiol.* 25, 428–430. doi: 10.1016/j.tim.2017.02.013

Auchtung, T. A., Fofanova, T. Y., Stewart, C. J., Nash, A. K., Wong, M. C., Gesell, J. R., et al. (2018). Investigating colonization of the healthy adult gastrointestinal tract by fungi. *mSphere* 3:e00092-18. doi: 10.1128/mSphere.00092-18

Banjara, N., Suhr, M. J., and Hallen-Adams, H. E. (2015). Diversity of yeast and mold species from a variety of cheese types. *Curr. Microbiol.* 70, 792–800. doi: 10.1007/s00284-015-0790-791

Bonifaz, A., Vázquez-González, D., Macías, B., Paredes-Farrera, F., Hernández, M. A., Araira, J., et al. (2010). Oral geotrichosis: report of 12 cases. *J. Oral Sci.* 52, 477–483. doi: 10.4103/0973-092X.157210

Bonini, A., Capatti, C., Parmeggiani, M., Gugliotta, L., Micozzi, A., Gentile, G., et al. (2008). Galactomannan detection in *Geotrichum* capitatum invasive infections: report of 2 new cases and review of diagnostic options. *Diagn. Microbiol. Infect. Dis.* 62, 450–452. doi: 10.1016/j.diagmicrobio.2008.08.008

Bouakline, A., Lacroix, C., Roux, N., Gangneux, J. P., and Derouin, F. (2000). Fungal contamination of food in hematological units. *J. Clin. Microbiol.* 38, 4272–4273.

Bougnoux, M. E., Brun, S., and Zahar, J. R. (2018). Healthcare-associated fungal outbreaks: new and uncommon species, new molecular tools for investigation and prevention. *Antimicrob. Resist. Infect. Control* 7:45. doi: 10.1186/s13756-018-0338-339

Brunetti, G., Visconti, V., Ghezzi, M. C., Mantovani, S., Ferretti, G., and Raponi, G. (2016). Management and treatment of magnusiomyces capitatus (*Geotrichum capitatum*) pleural infection in a non-neutropenic patient with posaconazole. *J. Clin. Microbiol.* 54, 1813–1821. doi: 10.1128/JCM.01640-1

De Hoog, G., and Smith, M. (2004). Ribosomal gene phylogeny and species delimitation in *Geotrichum* and its teleomorphs. *Front. Microbiol.* 7:1629. doi: 10.3389/fmicb.2016.01629

De Almeida Júnior, J. N., Slatajnbok, J., da Silva, A. R., Vieira, V. A., Galasti, A. L., Bisoli, L., et al. (2016). Rapid identification of moulds and arthroconidial yeasts from positive blood cultures by MALDI-TOF mass spectrometry. *Med. Mycol.* 54, 885–889. doi: 10.1177/1369378615595860

De Hoog, G., and Smith, M. (2004). Ribosomal gene phylogeny and species delimitation in *Geotrichum* and its teleomorphs. *Stud. Mycol.* 50, 489–515.

De Hoog, G. S., Smith, M. T., and Guého, E. (1986). A revision of the genus *Geotrichum* in its teleomorphs. *Stud. Mycol.* 29, 1–131.

De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., et al. (2008). Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. *Clin. Infect. Dis.* 46, 1813–1821. doi: 10.1086/588660

Del Principe, M. I., Sarmati, L., Cefalo, M., Fontana, C., De Santis, G., Buccirosso, F., et al. (2016). A cluster of *Saprochaete clavata* infection in haematological patients: a first Italian report and review of literature. *Mycoses* 59, 594–601. doi: 10.1111/myc.12508

**AUTHOR CONTRIBUTIONS**

VB contributed conception and design of the study, analyzed and interpreted the patient and microbiological data, and wrote the manuscript. RB analyzed and interpreted the patient data regarding molecular analysis. EH analyzed and interpreted the patient data regarding the hematological disease. OC and DS reviewed the manuscript and provided FungiScope data. PŻ analyzed and interpreted the patient data regarding the hematological disease and wrote the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

**FUNDING**

This work was supported by program PROGRES Q40/08.

**ACKNOWLEDGMENTS**

We thank Cyrus Rasti, M.D. for language editing.
Desnos-Ollivier, M., Blanc, C., Garcia-Hermoso, D., Hoinard, D., Alanio, A., and Dromer, F. (2014). Misidentification of *Saprochaete clavata* as *Magnusomyces capitatus* in clinical isolates: utility of internal transcribed spacer sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry and importance of reliable databases. *J. Clin. Microbiol.* 52, 2196–2198. doi: 10.1128/JCM.00339-14

Desnos-Ollivier, M., Bretagne, S., Boullé, A., Gautier, C., Dromer, F., Lortholary, O., et al. (2019). Isavuconazole MICs distribution of 29 yeast species responsible for invasive infections (2015-2017). *Clin. Microbiol. Infect.* 25, 634.e1–634.e4. doi: 10.1016/j.cmi.2019.02.007

Durán Graeff, L., Seidel, D., Vehreschild, M. J., Happonen, A., Kindo, A., Racil, Z., et al. (2017). Invasive infections due to *Saprochaete* and *Geotrichum* species: report of 23 cases from the fungoscope registry. *Mycoses* 60, 273–279. doi: 10.1111/myc.12631

Esposto, M. C., Prigatano, A., Lo Cascio, G., Ossi, C., Grancini, A., Cavanna, C., et al. (2018). Yeast-like filamentous fungi: molecular identification and in vitro susceptibility study. *Med. Mycol.* 57, 909–913. doi: 10.1093/yny/mny055

Favre, S., Rougeron, A., Levoir, L., Pérand, B., Milpied, N., Acceberery, L., et al. (2016). *Saprochaete clavata* invasive infection in a patient with severe aplastic anemia: efficacy of voriconazole and liposomal amphotericin B with adjuvant granulocyte transfusions before neutrophil recovery following allogeneic bone marrow transplantation. *Med. Mycol. Case Rep.* 11, 21–23. doi: 10.1016/j.mmcr.2016.03.001

Fernández-Ruiz, M., Guinea, J., Puig-Assensio, M., Zaragoza, Ó, Almirante, B., Cuenca-Estrella, M., et al. (2017). *S. capitata* growth and morphogenesis. *J. Clin. Microbiol.* 55, 125–136. doi: 10.1093/yny/mwy055

Gadea, I., Cuenca-Estrella, M., Prieto, E., Díaz-Guerra, T. M., García-Cia, J. I., Fernández-Ruiz, M., Guinea, J., Puig-Asensio, M., Zaragoza, Ó, Almirante, B., Hallen-Adams, H. E., and Suhr, M. J. (2017). Fungi in the healthy human gastrointestinal tract. *Virulence* 8, 352–358. doi: 10.1080/21505594.2016.1247140

Hawksworth, D. L., Crous, P. W., Redhead, S. A., Reynolds, D. R., Samson, R. A., Seifert, K. A., et al. (2011). The Amsterdam declaration on fungal nomenclature. *IMA Fungus* 2, 105–112. doi: 10.5590/imafung.2011.02.01.14

Hazen, K. C. (1995). New and emerging yeast pathogens. *Clin. Microbiol. Rev.* 8, 462–478. doi: 10.1128/CMR.8.4.462

Henrich, T. J., Marty, F. M., Müller, D. A. Jr., and Thörner, A. R. (2009). Disseminated *Geotrichum* candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. *Transpl. Infect. Dis.* 11, 458–462. doi: 10.1111/j.1369-3620.2009.00418.x

Kaplan, E., Al-Hatmi, A. M., Ilkit, M., Gerrits van den Ende, A. H. G., Hagen, F., Meis, J. F., et al. (2017). Molecular diagnostics of arthroconidial yeasts, frequent pulmonary opportunists. *J. Clin. Microbiol.* 56:e01427-17. doi: 10.1128/JCM.01427-17

Kelly, L. P., Chong Nguyen, C., Palmieri, L. J., Pallav, K., Dowd, S. E., Humbert, L., et al. (2019). *Saccharomyces boulardii* CNCM I-745 modulates the f把控 bile acids metabolism during antimicrobial therapy in healthy volunteers. *Front. Microbiol.* 10:336. doi: 10.3389/fmicb.2019.00336

Kolecka, A., Khayhan, K., Groenewald, M., Theelen, B., Arabatzis, M., Veghakgi, A., et al. (2013). Identification of medically relevant species of arthroconidial yeasts by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J. Clin. Microbiol.* 51, 2491–2500. doi: 10.1128/JCM.00470-13

Lacroix, C., Brethorn, B., Bossel, N., Desnos, M., Leblanc, T., Rafioux, E., et al. (2007). *Geotrichum* clavatum an emerging pathogen responsible for invasive infection in two neutropenic leukemia patients [abstract P180]. *J. Chemother.* 19(Suppl. 3):81.

Leoni, M., Riccardi, N., Rotullo, G. A., Godano, E., Faraci, M., Bandettini, R., et al. (2018). Magnusomyces clavatus infection in a child after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic implications. *Med. Mycol. Case Rep.* 23, 65–67. doi: 10.1016/j.mmcr.2018.12.005

Li, J., Chen, D., Yu, B., He, J., Zheng, P., Mao, X., et al. (2018). Fungi in gastrointestinal tracts of human and mice: from community to functions. *Microb. Ecol.* 75, 821–829. doi: 10.1007/s00248-017-1105-9

Liao, Y., Hartmann, T., Ao, J. H., and Yang, R. Y. (2012a). Serum glucronoxylomannan may be more appropriate for the diagnosis and therapeutic monitoring of *Trichosporon* fungemia than serum β-D-glucan. *Int. J. Infect. Dis.* 16:e638. doi: 10.1016/j.ijid.2012.03.009

Liao, Y., Hartmann, T., Zheng, T., Yang, R. Y., Ao, J. H., and Wang, W. L. (2012b). Breakthrough *Trichosporosis* in patients receiving echinocandins: case report and literature review. *Chin. Med. J.* 125, 2632–2635.

Liu, X., Zhou, W., Jiang, Y., and Kuang, L. (2018). Invasive fungal infection caused by *Geotrichum* clavatum in an acute leukemia child: first documented case from mainland China. *Jpn J. Infect. Dis.* 72, 130–132. doi: 10.7888/jvid.01673-3099(2012)00174-3

Liu, Y., Hartmann, T., Zheng, T., Yang, R. Y., Ao, J. H., and Wang, W. L. (2012). Serum levels of crushed posaconazole delayed release tablets. *Antimicrob. Agents Chemother.* 63:e02688-18. doi: 10.1128/AAC.02688-18

Meletiadis, J., and Roulides, E. (2013). Rare invasive fungal infections: epidemiology, diagnosis and management. *Carr. Infect. Dis. Rep.* 7, 351–360. doi: 10.1186/s12281-013-0155-9

Miceli, M. H., Diaz, J. A., and Lee, S. A. (2011). Emerging opportunistic yeast infections. *Lancet Infect. Dis.* 11, 142–151. doi: 10.1016/S1473-3099(10)70218-7

Miceli, M. H., and Kauffman, C. A. (2015). Isavuconazole: a new broad-spectrum triazole antifungal agent. *Clin. Infect. Dis.* 61, 1558–1565. doi: 10.1093/cid/civ571

Millar, B. C., Xu, J., Moore, J. E., and Earle, J. A. P. (2000). A simple and sensitive method to extract bacterial, yeast and fungal DNA from blood culture material. *J. Microbiol. Meth.* 42, 139–147. doi: 10.1016/S0167-7012(00)00174-3

Nakase, K., Suzuki, K., Kyo, T., Kohara, T., Sugawara, Y., and Katayama, N. (2012). Is elevation of the serum β-D-glucan level a paradoxical sign for *Trichosporon* fungemia in patients with hematologic disorders? *Int. J. Infect. Dis.* 16, e2–4. doi: 10.1016/j.ijid.2011.09.017

Ofadazi, B., Pietzneck, V. L., Rodriguez, J. R., Chen, E., McGinnis, M. R., and Ostrosky-Zeichner, L. (2006). Differences in beta-glucan levels in culture supernatants of a variety of fungi. *Med. Mycol.* 44, 267–272. doi: 10.1080/13693700500474327
Owusu Obeng, A., Egelund, E. F., Alsultan, A., Peloquin, C. A., and Johnson, J. A. (2014). CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? *Pharmacology, 73*, 703–718. doi: 10.1002/phar.1400

Pfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., and Castanheira, M. (2015). Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. *Diagn. Microbiol. Infect. Dis.*, 82, 303–313. doi: 10.1016/j.diagmicrobio.2015.04.008

Picard, M., Cassaing, S., Letocart, P., Verdeil, X., Protin, C., Chauvin, P., et al. (2013). *Saprochaete clavata* to June 2011. *Eur. J. Clin. Microbiol. Infect. Dis.*, 32, 289–294. doi: 10.1007/s11932-012-1661-3

Salgüero Fernández, I., Nájera Botello, L., Orden Martinez, B., and Roustan Gullón, Pimenta, R. S., Alves, P. D., Almeida, G. M., Silva, J. F., Morais, P. B., Schiemann, R., Glasmacher, A., Bailly, E., Horré, R., Molitor, E., Leutner, C., et al. (2014). High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J. Clin. Oncol.*, 32, 219–228. doi: 10.1200/JCO.2013.53.3838

Walsh, T. J., Melcher, G. P., Rinaldi, M. G., Lecciones, J., McGough, D. A., Kelly, P., et al. (1998). *Trichosporon asahii* causing nosocomial aspergillosis in adult patients in the United States, 2000–2013. *Open Forum Infect. Dis.*, 4:eofv268. doi: 10.1093/ofid/ofv268

Walsh, T. J., Melcher, G. P., Rinaldi, M. G., Lecciones, J., McGough, D. A., Kelly, P., et al. (1990). *Trichosporon asahii* beigeli, an emerging pathogen resistant to amphotericin B. *J. Clin. Microbiol.*, 28, 1616–1622.

Wang, W., Wang, J., Li, J., Yan, P., Jin, Y., Zhang, R., et al. (2018). Cholecystectomy damages aging-associated intestinal microbiota construction. *Front. Microbiol.*, 9:1402. doi: 10.3389/fmicb.2018.01402

Willems, R., Sucià, S., Meloni, G., Labar, B., Marie, J. P., Halkes, C. J., et al. (2014). High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J. Clin. Oncol.*, 32, 219–228. doi: 10.1200/JCO.2013.51.8571

Yi, W. M., Schoepfner, K. E., Jaeger, J., Mueller, S. W., MacLaren, R., Fish, D. N., et al. (2017). Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. *Ann. Clin. Microbiol. Antimicrob.*, 16:60. doi: 10.1186/s12941-017-0235-2

Zalar, P., Novak, M., de Hoog, G. S., and Gunde-Cimerman, N. (2009). Yeast communities in two atlantic rain forest fragments in southeast Brazil. *Braz. J. Microbiol.*, 40, 303–313. doi: 10.1016/j.diagmicrobio.2008.10.002

Corrêa, A. Jr., et al. (2009). Yeast communities in two atlantic rain forest fragments in southeast Brazil. *Braz. J. Microbiol.*, 40, 303–313. doi: 10.1016/j.diagmicrobio.2008.10.002

Frontiers in Microbiology | www.frontiersin.org 18 October 2019 | Volume 10 | Article 2196

Copyright © 2019 Buchta, Bolehovská, Hovorková, Cornely, Seidel and Žák. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.